<DOC>
	<DOC>NCT01489046</DOC>
	<brief_summary>The purpose of this study is to identify at least one dose of BMS-986001 which is safe, well tolerated, and efficacious when combined with Efavirenz (EFV) + Lamivudine (3TC) for treatment-naive Human Immunodeficiency Virus 1 (HIV-1) infected subjects</brief_summary>
	<brief_title>Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive</brief_title>
	<detailed_description>Double Blind through Week 24. Partially Blind (to subjects, caregivers, Investigators) through Week 48.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>At least 18 years of age, (or minimum age as determined by local regulatory or as legal requirements dictate, whichever is higher) Plasma HIV1 RNA &gt; 5000 copies/mL Antiretroviral treatmentnaive; defined as no current or previous exposure to &gt; 1 week of an antiretroviral drug CD4+ Tcell count &gt; 200 cells/mm3 Resistance to any of the study medications [Tenofovir Disoproxil Fumarate(TDF), Efavirenz (EFV), Lamivudine (3TC)] or to HIV Protease Inhibitors (PIs) Contraindications to any of the study drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>